A detailed history of Simplex Trading, LLC transactions in Liquidia Corp stock. As of the latest transaction made, Simplex Trading, LLC holds 13,562 shares of LQDA stock, worth $136,026. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,562
Previous 25,890 47.62%
Holding current value
$136,026
Previous $310,000 56.45%
% of portfolio
0.0%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$8.9 - $14.11 $109,719 - $173,948
-12,328 Reduced 47.62%
13,562 $135,000
Q2 2024

Jul 25, 2024

BUY
$11.96 - $15.71 $100,188 - $131,602
8,377 Added 47.83%
25,890 $310,000
Q1 2024

Apr 25, 2024

SELL
$11.35 - $16.73 $941,346 - $1.39 Million
-82,938 Reduced 82.57%
17,513 $258,000
Q4 2023

Feb 02, 2024

BUY
$5.77 - $12.19 $363,879 - $768,750
63,064 Added 168.68%
100,451 $1.21 Million
Q3 2023

Nov 01, 2023

BUY
$6.27 - $8.15 $62,236 - $80,896
9,926 Added 36.15%
37,387 $237,000
Q2 2023

Aug 04, 2023

BUY
$6.63 - $9.9 $149,625 - $223,423
22,568 Added 461.23%
27,461 $215,000
Q1 2023

Apr 27, 2023

SELL
$5.72 - $7.91 $32,318 - $44,691
-5,650 Reduced 53.59%
4,893 $33,000
Q4 2022

Feb 02, 2023

BUY
$4.68 - $6.54 $49,341 - $68,951
10,543 New
10,543 $67,000
Q2 2022

Aug 03, 2022

SELL
$3.37 - $7.55 $63,005 - $141,154
-18,696 Closed
0 $0
Q1 2022

May 02, 2022

SELL
$5.14 - $7.38 $3,649 - $5,239
-710 Reduced 3.66%
18,696 $134,000
Q4 2021

Feb 23, 2022

BUY
$2.71 - $5.17 $25,934 - $49,476
9,570 Added 97.3%
19,406 $94,000
Q2 2021

Aug 12, 2021

BUY
$2.51 - $3.11 $24,688 - $30,589
9,836 New
9,836 $28,000
Q4 2020

Feb 02, 2021

SELL
$2.6 - $5.79 $7,943 - $17,688
-3,055 Closed
0 $0
Q3 2020

Oct 14, 2020

BUY
$4.34 - $8.28 $13,258 - $25,295
3,055 New
3,055 $15,000

Others Institutions Holding LQDA

About Liquidia Corp


  • Ticker LQDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,362,300
  • Market Cap $646M
  • Description
  • Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...
More about LQDA
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.